Education
About Us
Working with TipRanks
Follow Us
ImmunoCellular Therapeutics (IMUC)
OTHER OTC:IMUC
IMUC Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.01 - $0.21
Previous CloseN/A
Volume63.00
Average Volume (3M)10.63K
Market Cap
$7.88M
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta0.24
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding113,270,750
10 Day Avg. Volume27,742
30 Day Avg. Volume10,632
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
IMUC FAQ
What was ImmunoCellular Therapeutics’s price range in the past 12 months?
ImmunoCellular Therapeutics lowest stock price was $0.01 and its highest was $0.20 in the past 12 months.
What is ImmunoCellular Therapeutics’s market cap?
ImmunoCellular Therapeutics’s market cap is $7.88M.
When is ImmunoCellular Therapeutics’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were ImmunoCellular Therapeutics’s earnings last quarter?
Currently, no data Available
Is ImmunoCellular Therapeutics overvalued?
According to Wall Street analysts ImmunoCellular Therapeutics’s price is currently Overvalued.
Does ImmunoCellular Therapeutics pay dividends?
ImmunoCellular Therapeutics does not currently pay dividends.
What is ImmunoCellular Therapeutics’s EPS estimate?
ImmunoCellular Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does ImmunoCellular Therapeutics have?
ImmunoCellular Therapeutics has 113,270,750 shares outstanding.
What happened to ImmunoCellular Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of ImmunoCellular Therapeutics?
Currently, no hedge funds are holding shares in IMUC
Company Description
ImmunoCellular Therapeutics
EOM Pharmaceuticals Holdings, Inc. is a clinical-stage biotechnology company, which engages in the development of drugs with the potential to transform therapeutic paradigms. Its pipeline includes EOM613 and EOM147. The company was founded on March 20, 1987 and is headquartered in Montvale, NJ.
ImmunoCellular Therapeutics (IMUC) Earnings & Revenues
Currently, no data available
Please return soon. This page is being updated.
Technical Analysis
Cellectar Biosciences
―
Akari Therapeutics
―
Sensei Biotherapeutics
―
Bolt Biotherapeutics
―
Calidi Biotherapeutics
―